Evaluation of the neuroprotector effect of an extract of stem bark of Mangifera indica L. (Vimang®) in patient with Spinocerebellar Hereditary Ataxia Type 2

Center of Pharmaceutical Chemistry0 个研究点目标入组 20 人开始时间: 2009年3月13日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

研究类型: Interventional
分配方式: Randomized controlled trial. Masking: Double Blind. Control group: Placebo. Assignment: Parallel. Purpose: Treatment

•1.Patients with diagnosis of SCA2 of any sex from 18 up to 60 years old, both inclusive.
•2. Patient able to develop basic activities of the daily life with independence (according to Barthel scale).
•3. Time of evolution of the illness until or smaller than 15 years.
•4. Patient that voluntarily accept to participate in the clinical trial, by means of the signature of the informed consent.

•1.Patients with antecedents of alcoholism.
•2. Patients with antecedents of any other illness with repercussion in the nervous system.
•3. Patient with non controlled chronic illnesses.
•4. Pregnancy or nursing.
•5. Patient with renal or hepatic failure.
•6. Patients with inmunosupresores tratment or with other antioxidant treatment.
•7. Patients that participate in another clinical trial.

发起方

Center of Pharmaceutical Chemistry